| Dr Matthew Vanderheiden, MD PHD | |
|
55 Fruit St Yaw 7, Massachusetts General Hospital, Boston, MA 02114 | |
| (617) 724-2241 | |
| Not Available |
| Full Name | Dr Matthew Vanderheiden |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 22 Years |
| Location | 55 Fruit St Yaw 7, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356312946 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 222812 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dana-farber Cancer Institute, Inc. | 9133038904 | 538 |
News Archive
Through the use of powerful genomic techniques, researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases have found that the development of immune cells, called innate lymphoid cells (ILCs), gradually prepares these cells for rapid response to infection. This work, which appeared online today in Cell, sheds light on the development and function of a cell type that is increasingly recognized as having an important role in the body's immune defense. NIAMS is part of the National Institutes of Health.
A diet high in refined carbohydrates may lead to an increased risk for new-onset depression in postmenopausal women, according to a study published in The American Journal of Clinical Nutrition.
To survive in his struggle against an aggressive form of prostate cancer, Bin McLaurin didn't only have to overcome the disease attacking his body. He said he also had to toss out his long-held image of masculinity.
The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.
Agenus Inc. announced today that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC on March 3, 2011 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Bid Price Requirement") because the bid price for the company's common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
› Verified 3 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346433257 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000142 |
News Archive
Through the use of powerful genomic techniques, researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases have found that the development of immune cells, called innate lymphoid cells (ILCs), gradually prepares these cells for rapid response to infection. This work, which appeared online today in Cell, sheds light on the development and function of a cell type that is increasingly recognized as having an important role in the body's immune defense. NIAMS is part of the National Institutes of Health.
A diet high in refined carbohydrates may lead to an increased risk for new-onset depression in postmenopausal women, according to a study published in The American Journal of Clinical Nutrition.
To survive in his struggle against an aggressive form of prostate cancer, Bin McLaurin didn't only have to overcome the disease attacking his body. He said he also had to toss out his long-held image of masculinity.
The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.
Agenus Inc. announced today that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC on March 3, 2011 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Bid Price Requirement") because the bid price for the company's common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
› Verified 3 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
Through the use of powerful genomic techniques, researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases have found that the development of immune cells, called innate lymphoid cells (ILCs), gradually prepares these cells for rapid response to infection. This work, which appeared online today in Cell, sheds light on the development and function of a cell type that is increasingly recognized as having an important role in the body's immune defense. NIAMS is part of the National Institutes of Health.
A diet high in refined carbohydrates may lead to an increased risk for new-onset depression in postmenopausal women, according to a study published in The American Journal of Clinical Nutrition.
To survive in his struggle against an aggressive form of prostate cancer, Bin McLaurin didn't only have to overcome the disease attacking his body. He said he also had to toss out his long-held image of masculinity.
The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.
Agenus Inc. announced today that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC on March 3, 2011 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Bid Price Requirement") because the bid price for the company's common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Vanderheiden, MD PHD Po Box 9142, Mass General Physician Organization, Charlestown, MA 02129-9142 Ph: (617) 724-0287 | Dr Matthew Vanderheiden, MD PHD 55 Fruit St Yaw 7, Massachusetts General Hospital, Boston, MA 02114 Ph: (617) 724-2241 |
News Archive
Through the use of powerful genomic techniques, researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases have found that the development of immune cells, called innate lymphoid cells (ILCs), gradually prepares these cells for rapid response to infection. This work, which appeared online today in Cell, sheds light on the development and function of a cell type that is increasingly recognized as having an important role in the body's immune defense. NIAMS is part of the National Institutes of Health.
A diet high in refined carbohydrates may lead to an increased risk for new-onset depression in postmenopausal women, according to a study published in The American Journal of Clinical Nutrition.
To survive in his struggle against an aggressive form of prostate cancer, Bin McLaurin didn't only have to overcome the disease attacking his body. He said he also had to toss out his long-held image of masculinity.
The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.
Agenus Inc. announced today that the company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC on March 3, 2011 indicating that the company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Bid Price Requirement") because the bid price for the company's common stock has closed below the minimum $1.00 per share requirement for 30 consecutive business days.
› Verified 3 days ago
Kaitlyn My-tu Lam, MBBS Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |